News-Medical -- Golimumab, a new tumour necrosis factor-a (TNF-a) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-a inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-a inhibitors, finds an Article published Online first and in this week’s edition of The Lancet.
